articleTop 1% cited
Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial
The Lancet · 2015 · Vol. 387(10027) · pp. 1540–1550
Roy S. Herbst✉(Yale Cancer Center)Paul Baas(Amsterdam UMC Location University of Amsterdam)Dong‐Wan Kim(Seoul National University Hospital)Enriqueta Felip(Vall d'Hebron Institute of Oncology)José Luis Perez‐Gracia(Clinica Universidad de Navarra)Ji‐Youn Han(National Cancer Center)Julian R. Molina(Mayo Clinic in Arizona)Joo-Hang Kim(CHA University Bundang Medical Center)Catherine Dubos Arvis(Centre François Baclesse)Myung‐Ju Ahn(Samsung Medical Center)Margarita Majem(Hospital de Sant Pau)Mary J. Fidler(Rush University Medical Center)Gilberto de Castro(Instituto do Câncer do Estado de São Paulo)Marcelo Garrido(Pontificia Universidad Católica de Chile)Gregory M. Lubiniecki(Merck & Co., Inc., Rahway, NJ, USA (United States))Yue Shentu(Merck & Co., Inc., Rahway, NJ, USA (United States))Ellie Im(Merck & Co., Inc., Rahway, NJ, USA (United States))Marisa Dolled‐Filhart(Merck & Co., Inc., Rahway, NJ, USA (United States))Edward B. Garon(University of California, Los Angeles)
Cancer Immunotherapy and BiomarkersLung Cancer Treatments and MutationsLung Cancer Diagnosis and TreatmentPembrolizumabDocetaxelMedicineLung cancerInternal medicinePopulationOncologyCancerGastroenterologySurgery
MeSH terms
DocetaxelAdultAgedAntineoplastic AgentsCarcinoma, Non-Small-Cell LungDrug Administration ScheduleFemaleHumansLung NeoplasmsMaleMiddle AgedGene Expression Regulation, NeoplasticTreatment OutcomeDisease-Free SurvivalPatient Selection
Funding
- Merck
Citations
6,477
FWCI
247.15
field-weighted impact
References
34
Percentile
100%
vs. same field & year
Citations per year
Cited by
Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer
New England Journal of Medicine · 2018 · 6,460 citations
Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study
The Lancet Oncology · 2016 · 1,385 citations
Review of Indications of FDA-Approved Immune Checkpoint Inhibitors per NCCN Guidelines with the Level of Evidence
Cancers · 2020 · 1,166 citations
Potential Predictive Value of <i>TP53</i> and <i>KRAS</i> Mutation Status for Response to PD-1 Blockade Immunotherapy in Lung Adenocarcinoma
Clinical Cancer Research · 2016 · 984 citations
<i>EGFR</i> Mutations and <i>ALK</i> Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non–Small Cell Lung Cancer: A Retrospective Analysis
Clinical Cancer Research · 2016 · 1,214 citations
Hyperprogressors after Immunotherapy: Analysis of Genomic Alterations Associated with Accelerated Growth Rate
Clinical Cancer Research · 2017 · 843 citations
Neurological adverse events associated with immune checkpoint inhibitors: Review of the literature
European Journal of Cancer · 2017 · 534 citations
Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry
Annals of Oncology · 2019 · 1,334 citations
References
B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion
Nature Medicine · 1999 · 2,463 citations
The PD‐1 pathway in tolerance and autoimmunity
Immunological Reviews · 2010 · 2,263 citations
Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion
Nature Medicine · 2002 · 4,970 citations
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
European Journal of Cancer · 2008 · 28,935 citations
Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
Science · 2015 · 7,864 citations
The blockade of immune checkpoints in cancer immunotherapy
Nature reviews. Cancer · 2012 · 13,550 citations
Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria
Clinical Cancer Research · 2009 · 3,204 citations
Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer
New England Journal of Medicine · 2015 · 9,391 citations
Citation Network
How this paper connects to the literature. Drag to explore, click any node to open that paper.